Contact Us
- 0904.634.288, 024.8888.4288
- [email protected]
- Facebook Fanpage: http://fb.com/dauthau.info
- Messenger: http://m.me/dauthau.info
Contact Us
| No | Medicine code | Active ingredient name | Technical criteria group | Concentration or content | How to use | Dosage form | Unit | Quantity | Feature |
|---|---|---|---|---|---|---|---|---|---|
1 |
N101 |
Combined vaccine to prevent Diphtheria-Pertussis-Tetanus |
Group 1 |
Each 0.5ml dose contains: - Tetanus toxoid 5 Lf; - Diphtheria toxin 2 Lf; - Acellular pertussis: Pertussis toxin (PT) 2.5mcg; Fibrous hemoglobin agglutinin (FHA) 5mcg; Pertactin (PRN) 3mcg; Stop factor 2 + 3 (FIM) 5mcg |
Inject |
Injection |
Vial/syringe/dose |
500 |
|
2 |
N102 |
Combined vaccine of 06 diseases: diphtheria - pertussis - tetanus - polio - hib and hepatitis B |
Group 1 |
Each 0.5ml dose contains: Diphtheria toxoid: not less than 20 IU; Tetanus toxoid: not less than 40 IU; Bordetella pertussis antigen: Pertussis toxoid (PT): 25mcg, Fibrin hemoglobin agglutinin (FHA): 25mcg; Polio virus (inactivated): Type 1 (Mahoney): 40 units of D antigen, Type 2 (MEF-1): 8 units of D antigen, Type 3 (Saukett): 32 units of D antigen; Hepatitis B surface antigen: 10mcg; Polysaccharide of Haemophilus influenzae type b (Polyribosylribitol Phosphate): 12mcg plus tetanus protein 22-36 mcg |
Inject |
Injection |
Vial/syringe/dose |
1.000 |
|
3 |
N103 |
Lower respiratory prevention vaccine caused by RSV |
Group 1 |
One dose (0.5ml after reconciliation) contains: antigen F stabilizes the collective fee of RSV subgroup A 0.06mg; The antigen F stabilizes the composite fee of RSV group B 0.06mg |
Inject |
Injection |
Vial/syringe/dose |
50 |
|
4 |
N104 |
Dengue prevention vaccine |
Group 1 |
Each vaccine 0.5ml after reconciliation contains: serum type 1 virus dengue (dengue fever) (living, reducing toxicity) ≥ 3.3 log 10 pfu; Serum tube 2 virus dengue (dengue virus) (living, reducing poison) ≥ 2.7 log 10 pfu; Serum tube 3 virus dengue (dengue virus) (living, reducing poison) ≥ 4.0 log 10 pfu; Serum tube 4 Virus Dengue (Dengue Virus) (Living, reducing poison) ≥ 4.5 log 10 pfu |
Inject |
Injection |
Vial/syringe/dose |
500 |
|
5 |
N105 |
Vaccine to prevent pneumonia and systemic infections caused by streptococcus |
Group 1 |
Pneumococcal polysaccharide type 1 serum 2.2mcg; Pneumococcal polysaccharide type 3 serum 2.2mcg; Pneumococcal polysaccharide type 4 serum 2.2mcg; Pneumococcal polysaccharide type 5 serum 2.2mcg; Serum type 6A pneumococcal polysaccharide 2.2mcg; Serum type 6B pneumococcal polysaccharide 4.4mcg; Serum type 7F pneumococcal polysaccharide 2.2mcg; Serum type 9V pneumococcal polysaccharide 2.2mcg; Serum type 10A pneumococcal polysaccharide 2.2mcg; Serum type 11A pneumococcal polysaccharide 2.2mcg, Serum type 12F pneumococcal polysaccharide 2.2mcg; Pneumococcal polysaccharide type 14 serum 2.2mcg; Serum type 15B pneumococcal polysaccharide 2.2mcg; Serum type 18C pneumococcal polysaccharide 2.2mcg; Serum type 19A pneumococcal polysaccharide 2.2mcg; Serum type 19F pneumococcal polysaccharide 2.2mcg; Serum type 22F pneumococcal polysaccharide 2.2mcg; Serum type 23F pneumococcal polysaccharide 2.2mcg ; Serum type 33F pneumococcal polysaccharide 2.2mcg; Plus CRM197 Carrier Protein 32mcg |
Inject |
Injection |
Vial/syringe/dose |
600 |
|
6 |
N106 |
Seasonal flu vaccine |
Group 1 |
Each dose of 0.5ml of vaccine (thin, inactive) contains: a/Victoria/4897/2022 (H1N1) PDM09 - Using the same strain (A/Victoria/4897/2022, IVR -238) 15MCG HA; A/Darwin/9/2021 (H3N2) - Use equivalent strains (a/darkwin/9/2021, IVR -228) 15mcg HA; B/Austria/1359417/2021 - Use equivalent strains (b/michigan/01/2021, wild strain) 15mcg HA; B/phuket/3073/2013 - Use the same strain (b/phuket/3073/2013, wild strain) 15mcg ha |
Inject |
Injection |
Vial/syringe/dose |
600 |
|
7 |
N501 |
Room vaccine |
Group 5 |
Antigen purified from wild virus strain L.pasteur 2061 Vero 15 passage, cultured on vero cells ≥ 2.5 IU/0.5ml |
Inject |
Injection |
Vial/syringe/dose |
1.200 |
|
8 |
N107 |
Metabolic brain room vaccine |
Group 1 |
Each dose of 0.5ml contains: polysaccharide brain meningococcal (serum a) (unit price plus)* 10mcg; Mocca brain polysaccharide (serum C) (unit price plus)*10mcg; Mocca polysaccharide (Serum group W135) (Collective unit price)* 10mcg; Polysaccharide brain meningococcal (serum medical group) (unit price plus) * 10mcg * is added to the carrier is a tetanus detoxification protein about 55mcg |
Inject |
Injection |
Vial/syringe/dose |
300 |
|
9 |
N502 |
Metabolic brain room vaccine |
Group 5 |
A 0.5ml dose of conjugate vaccine combines group B meningococcal outer membrane protein (50 µg) and group C meningococcal cortical polysaccharide (50 µg). |
Inject |
Injection |
Vial/syringe/dose |
500 |
|
10 |
N108 |
Cervical cancer prevention vaccine |
Group 1 |
Each dose of 0.5ml contains 30mcg protein L1 HPV type 6; 40mcg protein L1 HPV type 11; 60mcg protein L1 HPV type 16; 40mcg protein l1 hpv type 18; 20mcg protein L1 HPV for each type 31,33,45,52 and 58 |
Inject |
Injection |
Vial/syringe/dose |
500 |
|
11 |
N401 |
Tetanus room vaccine |
Group 4 |
Detoxification refined tetanus ≥ 40 IU/0.5ml |
Inject |
Injection |
Vial/syringe/dose |
1.000 |
|
12 |
N109 |
Hepatitis A and B vaccine |
Group 1 |
Each dose of 1ml contains hepatitis A virus antigen (HM175 Strain) 720 Elisa Units; R-DNA Hepatitis B Virus Surface Antigen (HBsAg) 20mcg |
Inject |
Injection |
Vial/syringe/dose |
100 |
|
13 |
N503 |
Hepatitis B vaccine |
Group 5 |
20mcg/ 1ml |
Inject |
Injection |
Vial/syringe/dose |
150 |
|
14 |
N504 |
Hepatitis B vaccine |
Group 5 |
10mcg/ 1ml |
Inject |
Injection |
Vial/syringe/dose |
300 |
|
15 |
N505 |
Japanese encephalitis vaccine |
Group 5 |
Each dose of 0.5 ml of reverting vaccine contains: Japanese encephalitis virus SA14-14-2 recombinant, living, reducing poison 4.0-5.8 log pfu |
Inject |
Injection |
Vial/syringe/dose |
300 |
|
16 |
N110 |
Polysaccharide vaccine is associated with protein D of Haemophilus Influenzae without tube |
Group 1 |
One dose (0.5ml) contains 1 mcg polysaccharide of serum types 11,2, 51,2, 6b1,2, 7f1,2, 9v1,2, 141,2, 23f1,2 and 3 mcg of serum types 41.2, 18C1.3, 19f1,4 |
Inject |
Injection |
Vial/syringe/dose |
2.000 |
Downloading files directly on the new Public Procurement System requires a computer using Windows operating system and installing Client Agent software (Linux and MacOS operating systems cannot install Client software yet). Therefore, to be able to download files on smartphones, tablets or computers using operating systems other than Windows, you need to use DauThau.info software to download files.
To download, please Login or Register
Select columns to display
If you are still not our member, please sign up.You can use your account on DauThau.info to log in to Dauthau.Net, and vice versa!
Only 5 minutes and absolutely free! Your account can be use on all over our ecosystem, including DauThau.info and DauThau.Net.
Detailed instructions on how to deposit money and redeem points on DauThau.info
When does contract negotiation fail?
[VIDEO] Guide for bid solicitors to Extend the Bid Submission Deadline
[VIDEO] Guide to Evaluating Bid Documents on the New National Bidding Network System
[VIDEO] Guide to Posting Tender Notices for PPP Projects
[VIDEO] Guide to Posting Prequalification Notices for PPP Projects
[VIDEO] Guide to Responding to Clarification Requests for e-HSMST (E-Prequalification Invitation Documents) of PPP Projects on the New National Bidding Network System
[VIDEO] Guide to Uploading the Shortlist for PPP Projects
Similar goods purchased by Investor BỆNH VIỆN SẢN - NHI CÀ MAU:
No similar goods purchased by the Investor were found.
Similar goods purchased by other Investor excluding BỆNH VIỆN SẢN - NHI CÀ MAU:
No similar goods have been found that other Investor have purchased.
Similar goods for which the bidding results of the Ministry of Health have been announced:
No similar goods have been found in the bidding results of the Ministry of Health.